[HTML][HTML] Emerging therapies against infections with Pseudomonas aeruginosa

B Tümmler - F1000Research, 2019 - ncbi.nlm.nih.gov
Infections with Pseudomonas aeruginosa have been marked with the highest priority for
surveillance and epidemiological research on the basis of parameters such as incidence …

[HTML][HTML] Therapeutic approaches for combating Pseudomonas aeruginosa infections

V Jangra, N Sharma, AK Chhillar - Microbes and Infection, 2022 - Elsevier
Pseudomonas aeruginosa is an opportunistic pathogen responsible for acute hospital-
acquired infections. This review described various therapeutic approaches to treat infections …

The Therapeutic Pipeline for Pseudomonas aeruginosa Infections

LL Burrows - ACS infectious diseases, 2018 - ACS Publications
Pseudomonas aeruginosa is a Gram-negative opportunistic pathogen, designated by the
World Health Organization as a critical priority for development of new therapeutics due to …

Novel therapeutic strategies for treating Pseudomonas aeruginosa infection

X Shao, Y Xie, Y Zhang, J Liu, Y Ding… - Expert Opinion on …, 2020 - Taylor & Francis
Introduction: Persistent infections caused by the superbug Pseudomonas aeruginosa and its
resistance to multiple antimicrobial agents are huge threats to patients with cystic fibrosis as …

The Epidemiology and Pathogenesis and Treatment of Pseudomonas aeruginosa Infections: An Update

D Reynolds, M Kollef - Drugs, 2021 - Springer
Pseudomonas aeruginosa is a Gram-negative bacterial pathogen that is a common cause of
nosocomial infections, particularly pneumonia, infection in immunocompromised hosts, and …

Therapeutic guidelines for Pseudomonas aeruginosa infections

H Giamarellou - International journal of antimicrobial agents, 2000 - Elsevier
Pseudomonas aeruginosa nowadays is encountered among the leading pathogen in (i) ICU
pneumonia;(ii) nosocomial bacteremia and AIDS primary bacteremia;(iii) iv drug users …

Recent advances in therapeutic targets identification and development of treatment strategies towards Pseudomonas aeruginosa infections

DRA Sanya, D Onésime, G Vizzarro, N Jacquier - BMC microbiology, 2023 - Springer
The opportunistic human pathogen Pseudomonas aeruginosa is the causal agent of a wide
variety of infections. This non-fermentative Gram-negative bacillus can colonize zones …

What Is New in the Anti–Pseudomonas aeruginosa Clinical Development Pipeline Since the 2017 WHO Alert?

S Reig, A Le Gouellec, S Bleves - Frontiers in Cellular and Infection …, 2022 - frontiersin.org
The spread of antibiotic-resistant bacteria poses a substantial threat to morbidity and
mortality worldwide. Carbapenem-resistant Pseudomonas aeruginosa (CRPA) are …

Antibiotic resistance in Pseudomonas aeruginosa and alternative therapeutic options

M Chatterjee, CP Anju, L Biswas, VA Kumar… - International Journal of …, 2016 - Elsevier
Pseudomonas aeruginosa is a leading cause of nosocomial infections and is responsible
for∼ 10% of all hospital-acquired infections worldwide. It continues to pose a therapeutic …

[HTML][HTML] Pseudomonas aeruginosa: Infections and novel approaches to treatment “Knowing the enemy” the threat of Pseudomonas aeruginosa and exploring novel …

N Sathe, P Beech, L Croft, C Suphioglu, A Kapat… - Infectious Medicine, 2023 - Elsevier
Pseudomonas aeruginosa is an aerobic Gram-negative rod-shaped bacterium with a
comparatively large genome and an impressive genetic capability allowing it to grow in a …